Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Institute for Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Transplant Cell Ther. 2023 Jun;29(6):391.e1-391.e7. doi: 10.1016/j.jtct.2023.03.013. Epub 2023 Mar 18.
Human adenovirus (HAdV) infection is a serious complication that can lead to significant morbidity and mortality, especially in immunocompromised pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Control and elimination of HAdV requires the presence of the respective antiviral T cells, and adoptive transfer of virus-specific T cells has become an important new treatment option for patients refractory to antiviral treatment. Although the adenoviral capsid protein hexon is known to be a major immunodominant T cell target across HAdV species, up to 30% of HAdV-seropositive donors show no T cell responses to the overlapping peptide pool spanning the entire protein. Our group recently verified the capsid protein penton as a second immunodominant target in HAdV infection. Here we aimed to investigate the prevalence of both penton-specific and hexon-specific HAdV T cells and their impact in virus control after HSCT. We analyzed the prevalence and characteristics of HAdV-specific T cells in 33 consecutive pediatric patients with HAdV reactivation following allogeneic HSCT and correlated them with viral load analysis. Our study demonstrates that penton is an important immunodominant target antigen of HAdV reactivation/ infection after HSCT in most patients. We demonstrate that in the majority of patients, both penton- and hexon-specific T cells appear at similar time intervals after transplantation. Despite the prevalence for either hexon-specific or penton-specific T cells in individual patients, we were unable to attribute the predominance to specific HLA types or HAdV serotypes. The occurrence of HAdV-specific T cells was closely linked to viral control, arguing for immune monitoring strategies to tailor antiviral treatment and adoptive T cell therapy.
人腺病毒(HAdV)感染是一种严重的并发症,可导致严重的发病率和死亡率,尤其是在接受异基因造血干细胞移植(HSCT)的免疫功能低下的儿科患者中。控制和消除 HAdV 需要存在相应的抗病毒 T 细胞,而针对病毒特异性 T 细胞的过继转移已成为对抗病毒治疗有抗性的患者的一种重要的新治疗选择。尽管腺病毒衣壳蛋白六邻体被认为是跨 HAdV 种系的主要免疫显性 T 细胞靶标,但高达 30%的 HAdV 阳性供体对跨越整个蛋白的重叠肽库没有 T 细胞反应。我们小组最近验证了衣壳蛋白五邻体是 HAdV 感染中的第二个免疫显性靶标。在这里,我们旨在调查 HAdV T 细胞对 penton 和 hexon 的特异性及其在 HSCT 后病毒控制中的作用。我们分析了 33 例连续接受异基因 HSCT 后发生 HAdV 再激活的儿科患者中 HAdV 特异性 T 细胞的流行率及其与病毒载量分析的相关性。我们的研究表明,在大多数患者中,penton 是 HSCT 后 HAdV 再激活/感染的重要免疫显性靶抗原。我们证明,在大多数患者中,penton-和 hexon-特异性 T 细胞在移植后相似的时间间隔出现。尽管在个体患者中存在针对 hexon 特异性或 penton 特异性 T 细胞的流行率,但我们无法将其优势归因于特定的 HLA 类型或 HAdV 血清型。HAdV 特异性 T 细胞的出现与病毒控制密切相关,这表明需要进行免疫监测策略来调整抗病毒治疗和过继性 T 细胞治疗。